The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

H Razavi; I Waked; C Sarrazin; RP Myers; R Idilman; F Calinas; W Vogel; MC Mendes Correa; C Hézode; P Lázaro; U Akarca; S Aleman; I Balık; T Berg; F Bihl; M Bilodeau; AJ Blasco; CE Brandão Mello; P Bruggmann; M Buti; JL Calleja; H Cheinquer; PB Christensen; M Clausen; HSM Coelho; ME Cramp; GJ Dore; W Doss; AS Duberg; MH El-Sayed; G Ergör; G Esmat; K Falconer; J Félix; MLG Ferraz; PR Ferreira; S Frankova; J García-Samaniego; J Gerstoft; JA Giria; FL Gonçales; E Gower; M Gschwantler; M Guimarães Pessôa; SJ Hindman; H Hofer; P Husa; M Kåberg; KDE Kaita; A Kautz; S Kaymakoglu; M Krajden; H Krarup; W Laleman; D Lavanchy; RT Marinho; P Marotta; S Mauss; C Moreno; K Murphy; F Negro; V Nemecek; N Örmeci; ALH Øvrehus; J Parkes; K Pasini; KM Peltekian; A Ramji; N Reis; SK Roberts; WM Rosenberg; F Roudot-Thoraval; SD Ryder; R Sarmento-Castro; D Semela; M Sherman; GE Shiha; W Sievert; J Sperl; P Stärkel; RE Stauber; AJ Thompson; P Urbanek; P Van Damme; I van Thiel; H Van Vlierberghe; D Vandijck; H Wedemeyer; N Weis; J Wiegand; A Yosry; A Zekry; M Cornberg; B Müllhaupt; C Estes

Journal article

The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

H Razavi, I Waked, C Sarrazin, RP Myers, R Idilman, F Calinas, W Vogel, MC Mendes Correa, C Hézode, P Lázaro, U Akarca, S Aleman, I Balık, T Berg, F Bihl, M Bilodeau, AJ Blasco, CE Brandão Mello, P Bruggmann, M Buti Show all

Journal of Viral Hepatitis | Published : 2014

DOI: 10.1111/jvh.12248

Abstract

The disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages. A modelling approach was used to estimate the total number of viremic infections, diagnosed, treated and new infections in 2013. In addition, the model was used to estimate the change in the total number of HCV infections, the disease progression and mortality in 2013-2030. Finally, expert panel consensus was used to capture current treatment practices in each country. Using today's treatment paradigm, the total number of HCV infections is projected to decline or remain flat in all countries studied. However, in the same time period, the number of individuals with late-stage liver disease i..

View full abstract

University of Melbourne Researchers

Alexander Thompson Author

Grants

Funding Acknowledgements

We are grateful to Daniela De Angelis, Ross Harris and Helen Harris at Public Health England for providing us with their calculated HCV progression rates prior to publication. Their progression rates by age cohort were instrumental in developing our estimates. We would also like to thank Rosie Thein for spending time with us discussing her elegant model for HCV progression rate. We would not have been able to get here without her help and guidance. Sylvie Deuffic-Burban, Henri Leleu and Martin Blachier were instrumental with our analysis of France's data. We are also grateful to Virginie Masserey, Jean-Luc Richard and Christian Schaetti of the Federal Office of Public Health (FOPH), who were incredibly generous with their time and data. A number of experts in Portugal provided us with their time and insights. We would like to thank the following individuals for their contribution - Dr. Alexandre Lourenco, Prof. Helena Cortez-Pinto, Dr. Joao Goulao, Luis Mendao, Prof. Paulo Ferrinho and Pedro Pita Barros. This project was supported by Gilead Sciences.